troglitazone has been researched along with Angioma in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Angioma: A vascular anomaly due to proliferation of blood or lymphatic vessels that forms a tumor-like mass. Vessels in the angioma may or may not be dilated.
| Excerpt | Relevance | Reference |
|---|
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duddy, SK | 1 |
| Parker, RF | 1 |
| Bleavins, MR | 1 |
| Gough, AW | 1 |
| Rowse, PE | 1 |
| Gorospe, S | 1 |
| Dethloff, LA | 1 |
| de la Iglesia, FA | 1 |
1 other study available for troglitazone and Angioma
| Article | Year |
|---|---|
p53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone.
Topics: Animals; Antioxidants; Chromans; DNA, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene | 1999 |